Stockreport

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

BioAge Labs, Inc.  (BIOA) 
Last bioage labs, inc. earnings: 8/3 07:00 am Check Earnings Report
US:NYSE Investor Relations: investor.bio-amber.com
PDF STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission o [Read more]